Clinical Trials for Dementia

Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).

This page lists clinical trials related to Dementia from the ClinicalTrials.gov database.

Trial Summary

• Total studies: 50
• Recruiting: 23
• Active, not recruiting: 6
• Completed: 12
• Other: 9

Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.

Recruiting Trials

NCT02014246 — Genetic Characterization of Movement Disorders and Dementias

Background:

There are two basic types of movement disorders. Some cause excessive movement, some cause slowness or lack of movement. Some of these are caused by mutations in genes. On the other hand, dementia is a condition of declining mental abilities, especially memory. Dementia can occur at any age but becomes more frequent with age. Researchers want to study the genes of families with a h…

NCT04576793 — Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer’s Disease

The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer’s disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer’s disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer’s disease…

NCT05806697 — Investigation of AlzHeimer’s Predictors in Subjective Memory Complainers - Extension Study

A regional, single-center, prospective, observational academic cohort will follow subjects who previously participated in the INSIGHT study and who agree an extension of their follow-up in the INSIGHT-2 research for additional 5-6 years. An annual multimodal evaluation (cognitive, oculomotor, biological and neuroimaging) will be proposed in order to describe the natural history of preclinical A…

NCT06585787 — A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer’s Disease (ADEPT-4)

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer’s Disease (AD) with moderate to severe psychosis related to AD.

NCT06651567 — A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer’s Dementia

This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer’s dementia

NCT07177352 — Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer’s Disease Studies

This study is a pre-screening process used to assess participants’ potential eligibility for Roche interventional Alzheimer’s disease studies.

NCT07033494 — A Clinical Study of MK-2214 in People With Early Alzheimer’s Disease (MK-2214-004)

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer’s disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person’s ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.

The goals of the study are…

NCT07142954 — Epidemiology and Biomarker Study in Alzheimer’s Disease

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts.

Participation in AACU will last approximately 7 years.

NCT06052254 — Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer’s Type

The primary objective of this study is to evaluate the efficacy of DMTS on frequency and severity of agitation associated with dementia of the Alzheimer’s type, compared with placebo.

NCT07170150 — A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer’s disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).

NCT07682155 — Study of the Brain’s Natural Cleaning System in Potential Organ Donors.

Alzheimer’s disease is a condition that affects the brain and is associated with the build-up of waste substances that can damage brain cells. Scientists have recently discovered a natural drainage and cleaning system around the brain, called the meningeal lymphatic system, which may help remove these waste products.

Researchers believe that this brain drainage system is connected to lymph nod…

NCT07445841 — Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training

The rates of cognitive decline and dementia after stroke are disproportionately high. Strategies that can protect the brain early after the stroke event could reduce the future risk of cognitive decline and dementia in these patients. Although physical exercise is usually recommended after stroke, there is very little information about the protective effect of exercise implemented in early stag…

NCT07347574 — NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer’s Detection in HK

Population aging is reshaping societal dynamics and presents significant global challenges. By 2050, it is projected that 1.6 billion people worldwide will be over the age of 65. Given that aging is the primary risk factor for many common chronic diseases, reducing the burden of age-related illnesses and promoting healthy aging have become critical public health priorities. Notably, Hong Kong h…

NCT07213700 — InRAD Observational Study

The goal of this international observational study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer’s disease (PwAD), by collecting real-world data from routine clinical practice across global clinical centers.

The InRAD Registry Observational Study has several aims:

• To collect medical information for many years from a large group of people with Alzhei…

NCT07681401 — Financial Counseling for Dementia Family Caregivers in Early and Middle Adulthood

The goal of this National Institutes of Health (NIH) Stage 1a study is to develop and pilot test a research- and community-informed financial counseling and advocacy (FCA) intervention for dementia family caregivers in early and middle adulthood. The main question it aims to answer is:

Is a research- and community-informed financial counseling and advocacy intervention usable, feasible and acc…

NCT07571161 — Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer’s Disease

The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer’s disease (AD).

The study drug will be administered intravenously (IV) (into a vein in the arm).

The study will last up to approximately 156 weeks, exc…

NCT07182357 — Designing Care Management for Hospice Transitions for Persons Living With Advanced Dementia

This study will test a care management intervention to guide end-of-life care and hospice transitions for persons with dementia and their care partners receiving home healthcare and ascertain feasibility, acceptability, fidelity, and usability of a dementia care management hospice transitions checklist. This study will also examine hospice enrollment, time to enrollment, and care partner satisf…

NCT07589595 — A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.

NCT07602582 — A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

NCT07685873 — Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease

To evaluate the potential usefulness of 18F-FPyCO/SMBT-1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-B-related disease patients.

NCT07673770 — Brain Wave Informed Non-invasive Brain Stimulation: Improving Neural Networks of Working Memory in Dementia: a Proof-of-concept Study

Working memory helps us hold information for a short time so one can think and make decisions. It keeps thoughts on track. As one gets older, working memory gets weaker. In people with dementia, it gets much worse, making it harder to talk with others, follow directions, or remember things like shopping lists.

This may happen because brain waves that support working memory fall out of sync. Re…

NCT07688460 — Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer’s Biomarkers

This study aims to evaluate the therapeutic efficacy of Lecanemab in patients with Alzheimer’s disease. The researchers will use a novel detection method based on mesoporous gold electrode surface-enhanced electrochemiluminescence (ECL) to monitor specific biomarkers in the patients’ plasma. By tracking changes in these biomarkers, the study seeks to determine how effectively Lecanemab treats t…

NCT07099053 — Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging

Background:

Some people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities. Amyloids are groups of proteins that develop in the brain and increase in number as people age. Researchers want to use imaging scans to track amyloids in people s brains over time. Their goal is to find out if any changes are related to cognitive decline or…

Active, Not Recruiting

NCT02994719 — Gait Analysis in Neurological Disease

The purpose of this study is to investigate whether speed-dependent measures of gait (so called gait signatures) can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.

NCT04692441 — Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain

High fat feeding (HFF) increases the risk of Alzheimer’s disease (AD) but individuals who carry the AD risk gene E4 paradoxically improve after acute HFF. The investigators propose to further study this phenomenon with a clinical study to assess cerebral blood flow which can be measured by a technique called arterial spin labeling (ASL) on an MRI and is tightly related to brain metabolism.

NCT05184569 — Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.

NCT06544616 — A Study of JNJ-64042056 in Participants With Preclinical Alzheimer’s Disease

The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.

NCT06814730 — A Study to Assess THN391 in Subjects With Alzheimer’s Disease

This is a Phase 1b study to evaluate different doses of the drug and see whether a drug is safe and how it behaves in the body.

THN391 has already been assessed in healthy people without Alzheimer’s disease. This is the first study of THN391 in patients with Early Alzheimer’s disease. Later studies will evaluate THN391 to see if it is effective for the treatment of Alzheimer’s disease.

In thi…

NCT07033481 — Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.

Not Yet Recruiting

NCT07690280 — Web-Based Psychoeducation for Dementia Caregivers

Behavioral and psychological symptoms of dementia (BPSD), such as agitation, anxiety, depression, sleep disturbance, and apathy, are common among people with dementia and often increase the burden on family caregivers. Many caregivers have limited knowledge and confidence in managing these symptoms.

This study aims to evaluate the effectiveness of a 6-week web-based psychoeducation and BPSD sy…

NCT07688213 — A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer’s Disease

This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer’s disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive impairment due to AD or mild AD dementia and with evidence of cerebral amyloid pathology.

This Ph…

NCT07690865 — Investigating the Effectiveness of Personalized Optimal Gamma Auditory Frequency Stimulation Intervention on Cognitive Function Enhancement

This study aims to evaluate whether personalized gamma-frequency auditory stimulation enhances cognitive function and brain synchronization. While 40 Hz auditory stimulation has been widely studied, recent evidence suggests optimal frequencies vary by individual. Using a cross-over design with 20 healthy adults, the research compares “optimal” versus “non-optimal” frequencies over one-month int…

NCT06042413 — Prediction and Prevention of Postoperative Mortality and Morbidity

This study will contribute to creating a prospective and automated preoperative risk assessment algorithm for predicting 30-day mortality, major adverse cardiac and cerebrovascular events (MACCE), and postoperative neurocognitive outcomes following elective cardiac and vascular surgery in older adults. It will evaluate associations between perioperative factors and longer-term neurocognitive ou…

NCT05987007 — Sleep Interventions and Neurocognitive Outcomes

This protocol focuses on the effect of sleep interventions on improving sleep and building cognitive/brain resilience in older adults with amnestic mild cognitive impairment and sleep disturbance. Two sleep interventions, cognitive behavioral therapy for insomnia (CBTI) and acoustic slow-wave activity enhancement (SWAE), will be utilized in a pilot randomized clinical trial in which participant…

NCT07690228 — A Phase 1 Study of GSM-779690T in Healthy Adult Participants

A Phase 1, single-centre, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple dose regimens of GSM-779690T in healthy adults. This first-in-human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSM-779690T.

NCT06021704 — The Care for America’s Aging Study

Care for America’s Aging is a randomized pilot study investigating whether a home health aide training intervention consisting of enhanced dementia-specific curriculum content will improve: 1) behavioral symptoms of older adult persons living with dementia or cognitive impairment (PLWD/CI) and 2) global health-related quality of life among PLWD/CI and their care partners.

NCT07686848 — Smartphone App for Adolescents With Idiopathic Scoliosis

This study aims to evaluate a smartphone application (DinSkoliose) designed to support adolescents with idiopathic scoliosis (AIS) in managing their condition and following their treatment.

Adolescents with AIS often find it challenging to adhere to conservative treatment, such as wearing a brace or performing physiotherapy exercises. The app was developed specifically for this study as a theo…

Enrolling by Invitation

NCT05617014 — Alzheimer’s Disease Neuroimaging Initiative 4

The Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer’s disease across the full disease spectrum. Building on the success of ADNI1, ADNI-GO, ADNI2, and ADNI3, ADNI4 integrates clinical, cognitive, imaging, genetic, and fluid biomarke…

Completed Trials

NCT01498263 — Inherited Diseases, Caregiving, and Social Networks

Approximately 66 million informal caregivers care for someone who is ill, disabled, or aged. These caregivers experience significant distress associated with caregiving, which may be particularly salient in the context of inherited conditions. Previous studies have not examined caregiving from a network perspective, nor have they considered how cognitive and emotional responses, such as caregiv…

NCT01925196 — Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation

Background:

- Some people have a mutation in the C9ORF72 gene that causes amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). The mutation causes a small piece of DNA to repeat itself thousands of times. The C9ORF gene mutation mostly occurs in families. In those families, some persons have ALS and others have FTD. Occasionally the C9ORF gene mutation occurs in persons witho…

NCT02821780 — CADASIL Disease Discovery

Cerebral autosomal dominant arteriopathy with subcortical infarct (CADASIL) is a lethal disease caused by a gene mutation that affects arteries in the brain. Symptoms include migraines, strokes, memory loss, and dementia. There are no treatments. Researchers want to study people who have CADASIL to learn more about it.

Objectives:

To learn more about CADASIL by studying people who have it.

E…

NCT04777396 — A Research Study Investigating Semaglutide in People With Early Alzheimer’s Disease (EVOKE)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer’s disease.

Participants will either get semaglutide or placebo (a “dummy” medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.

The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 …

NCT04894006 — Dementia Family Caregiver Study

The proposed study will test a 3-month, community health worker (CHW) delivered home visit, culturally and language-appropriate intervention for ethnic and underserved dementia family caregivers of persons with dementia (PWD) using wearable technology for real time monitoring of caregivers’ stress and sleep. The CHW delivered home visit intervention includes stress reduction techniques by mindf…

NCT05138848 — Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer’s Disease

Dementia caused by Alzheimer’s disease affects approximately 5.6 million adults over age 65, with costs expected to rise from $307 billion to $1.5 trillion over the next 30 years. Behavioral interventions have shown promise for mitigating neurodegeneration and cognitive impairments. Sleep is a modifiable health behavior that is critical for cognition and deteriorates with advancing age and Alzh…

NCT05356702 — The Brain Health Study: A Pragmatic, Patient-Centered Trial

The eRADAR Brain Health Study seeks to refine and test a novel, low-cost strategy for increasing dementia detection within primary care.

NCT05381090 — Circulating Ghrelin as a Biomarker for Dementia

The primary objective of this study will explore whether circulating acyl-ghrelin (AG) and unacylated-ghrelin (UAG) are reduced in neurodegenerative disease associated with cognitive impairment. It will focus on validating pilot data generated following the analysis of Parkinson’s disease (PD), Parkinson’s disease dementia (PDD) and healthy cohorts (IRAS project ID: 250933). In addition to the …

NCT05584241 — Behavioral Change Following Alzheimer’s Disease (AD) Biomarker Disclosure

The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron emission tomography-based amyloid and tau burden and associated risk of conversion to Dementia-Alzheimer’s Type. Healthcare access will be explored as potential barrie…

NCT06489015 — Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials

This clinical trial is an open-label, parallel-group, exploratory study of recombinant human serum albumin in patients with mild to moderate Alzheimer’s Disease (AD).

NCT06815965 — A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.

NCT07364825 — Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care

The goal of this pilot randomized controlled trial is to learn if adult patients with acute psychiatric conditions can receive hospital-level care at home. The main question it aims to answer is:

1. Estimate the eligibility rate for BHH among screened patients. What percentage of eligible patients agree to enroll in behavioral health home hospital (intervention)?